On or around 11/21/2017 (Ongoing date of last review)
Filing Date: November 20, 2017
Array is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s lead cancer drug binimetinib (MEK162) was evaluated in multiple trials and combinations, including a Phase 3 “NEMO” study versus dacarbazine in unresectable or metastatic NRAS-mutant melanoma patients.
According to the law firm press release, the complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Array’s NEMO study failed to show sufficient clinical benefit of the binimetinib NDA in use for patients with NRAS-mutant melanoma; (2) it was aware that this lack of supporting data would not be sufficient to receive FDA approval of binimetinib in use for patients with NRAS-mutual melanoma; and (3) as a result of the foregoing, Array’s public statements were materially false and misleading at all relevant times.
Company & Securities Information
Defendant: Array Biopharma Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: ARRY
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Wendell Rose, et al. v. Array Biopharma Inc., et al.
COURT: D. Colorado
DOCKET #: 17-CV-02789
JUDGE: Hon. Kristen L. Mix
DATE FILED: 11/20/2017
CLASS PERIOD START: 12/16/2015
CLASS PERIOD END: 03/17/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Berens Law LLC 2373 Central Park Boulevard Suite 100, Berens Law LLC , CO 80238 303-861-1764 303-395-0393 ·
Levi & Korsinsky, LLP 30 Broad Street, 15 1h Floor, Levi & Korsinsky, LLP, NY 10004 212.363.7500 212.363-7171 ·
First Identified Complaint (FIC) Filings:
Class Action Complaint for Violation of the Federal Securities Laws